Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Current treatments for diabetic erectile dysfunction, such as phosphodiesterase type 5 inhibitors, penile injection, or vacuum erection devices, primarily offer symptomatic relief and do not address the underlying pathophysiology, which involves neural, vascular, and smooth muscle degeneration.
Objectives: This study aimed to evaluate the therapeutic potential of amniotic fluid-derived stem cells in a rat model of diabetic erectile dysfunction by assessing their impact on erectile function and penile tissue regeneration.
Methods: Male Sprague‒Dawley rats were divided into control, diabetic, and amniotic fluid-derived stem cell-treated diabetic groups. Diabetes was induced using streptozotocin (60 mg/kg). Five weeks after intracavernous injection of amniotic fluid-derived stem cells (1 × 10 cells per rat), erectile function, penile nerves, endothelial cells, and smooth muscle cells were evaluated through intracavernous pressure measurements, histological analyses, and cellular senescence assessments using class III β-tubulin (TUBB3), rat endothelial cell antigen, and α-smooth muscle actin markers, respectively, along with β-galactosidase staining.
Results: Amniotic fluid-derived stem cell treatment significantly improved erectile function in diabetic rats, as evidenced by increased intracavernous pressure/mean arterial pressure ratios than untreated diabetic rats (p = 0.0307). Immunofluorescence revealed restoration of neuronal and endothelial markers, while α-smooth muscle actin expression increased and β-galactosidase activity decreased, indicating enhanced smooth muscle integrity and reduced cellular senescence.
Conclusion: Intracavernous amniotic fluid-derived stem cell therapy effectively restores erectile function and mitigates tissue damage in diabetic rats by promoting neurovascular regeneration and reducing senescence, highlighting amniotic fluid-derived stem cells as a promising regenerative therapy for diabetic erectile dysfunction and supporting further pre-clinical and clinical investigations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/andr.70117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amniotic fluid stem cell therapy improves erectile function in a diabetic rat model.
Andrology
September 2025
Department of Urology, Knuppe Molecular Urology Laboratory, School of Medicine, University of California, San Francisco, California, USA.
Background: Current treatments for diabetic erectile dysfunction, such as phosphodiesterase type 5 inhibitors, penile injection, or vacuum erection devices, primarily offer symptomatic relief and do not address the underlying pathophysiology, which involves neural, vascular, and smooth muscle degeneration.
Objectives: This study aimed to evaluate the therapeutic potential of amniotic fluid-derived stem cells in a rat model of diabetic erectile dysfunction by assessing their impact on erectile function and penile tissue regeneration.
Methods: Male Sprague‒Dawley rats were divided into control, diabetic, and amniotic fluid-derived stem cell-treated diabetic groups.
Aging Adipose-Derived Mesenchymal Stem Cells, Cultured on a Native Young Extracellular Matrix, Are Protected From Senescence and Apoptosis Along With Increased Expression of HLA-DR and CD74 Associated With PI3K Signaling.
Aging Cell
August 2025
Department of Comprehensive Dentistry, UT Health San Antonio, School of Dentistry, San Antonio, Texas, USA.
Older adults are the primary population for cell-based therapies for age-related diseases, but the efficacy of administering autologous mesenchymal stem cells (MSCs) is impaired due to biological aging. In the present study, we cultured aging adipose (AD)-derived MSCs from > 65-year-old donors on extracellular matrix (ECM) synthesized by human amniotic fluid-derived pluripotent stem cells (ECM Plus) versus tissue culture plastic (TCP) and hypothesized that ECM Plus provided an ideal "young" microenvironment for reactivating and preserving early-stage progenitor cells within aging AD-MSCs. To test our hypothesis, we serially sub-cultured aging AD-MSCs on ECM Plus or TCP and characterized the cells both phenotypically and functionally, and then analyzed the cells at the single-cell transcriptomic level for the mechanisms that control cell fate.
View Article and Find Full Text PDFAmniotic fluid collected from vaginal birth as a source of stem cells for clinical applications and disease modeling.
Stem Cells Transl Med
June 2025
Department of Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.
Importance: Amniotic fluid is a promising source of autologous cells for disease modeling, drug screening, and regenerative medicine applications. However, current methods of collecting amniotic fluid are invasive, and samples are limited to pregnancies that require amniocentesis or cesarean section.
Objective: The purpose of this study was to determine whether amniotic fluid cells could be isolated and cultured from amniotic fluid collected during vaginal deliveries.
Amniotic fluid MSCs for scaffold-free cartilage repair: spheroid fusion and chondrogenic microtissue development.
Future Sci OA
December 2025
Department of Orthopedics, Rheumatology and Traumatology, School of Medical Sciences, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Background: Articular cartilage injuries are challenging due to limited regenerative capacity, causing chronic pain and impaired mobility. Current treatments are often inadequate, necessitating novel cartilage repair approaches. This study investigates amniotic fluid-derived mesenchymal stromal cells (AF-MSC) as a promising cell source for tissue engineering.
View Article and Find Full Text PDFProteomic analysis of secreted proteins derived from amniotic fluid stem cells.
Cell Tissue Res
September 2025
Stem Cell Bank Unit, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Prannok Road, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand.
Mesenchymal stem cells (MSCs) show promising therapeutic effects due to the proteins they secrete. However, MSCs from different sources exhibit only 60% similarity of proteins they secrete, suggesting that unique proteins may offer distinct therapeutic properties based on their origin. Amniotic fluid-derived MSCs (AFSCs) are promising for treating degenerative diseases and are unique in providing sufficient cells for fetal therapies.
View Article and Find Full Text PDF